1. Introduction {#sec1-marinedrugs-17-00146}
===============

Coral reef architecture comes from the deposition of massive calcium carbonate skeletons secreted by scleractinian corals, or hard corals \[[@B1-marinedrugs-17-00146]\]. These corals represent the habitat for a vast diversity of organisms \[[@B2-marinedrugs-17-00146]\]. They live in intimate symbiosis with unicellular dinoflagellate symbionts, commonly called zooxanthellae, which are hosted in the coral tissues. The enzymes carbonic anhydrases (CAs, EC 4.2.1.1) play major roles in two essential processes of coral's physiology; they are involved in the carbon supply for calcium carbonate precipitation (formation of skeletons) as well as in carbon-concentrating mechanisms for symbiont photosynthesis \[[@B3-marinedrugs-17-00146]\]. Numerous studies have shown CAs are ubiquitous metallo-enzymes, which are responsible for the reversible hydration of CO~2~ to bicarbonate (HCO~3~^−^), carbonate (CO~3~^2−^), and protons (H^+^) \[[@B2-marinedrugs-17-00146],[@B4-marinedrugs-17-00146],[@B5-marinedrugs-17-00146],[@B6-marinedrugs-17-00146],[@B7-marinedrugs-17-00146],[@B8-marinedrugs-17-00146],[@B9-marinedrugs-17-00146],[@B10-marinedrugs-17-00146],[@B11-marinedrugs-17-00146],[@B12-marinedrugs-17-00146],[@B13-marinedrugs-17-00146],[@B14-marinedrugs-17-00146],[@B15-marinedrugs-17-00146]\]. In the biological systems, the CO~2~, HCO~3~^−^, CO~3~^2−^, and H^+^ are interconnected by equilibrium reactions, and their concentrations are regulated by CAs \[[@B5-marinedrugs-17-00146],[@B16-marinedrugs-17-00146],[@B17-marinedrugs-17-00146],[@B18-marinedrugs-17-00146],[@B19-marinedrugs-17-00146]\]. Thus, these enzymes play a crucial role in several physiological processes such as respiration, inorganic carbon transport, intra and extra-cellular pH regulation, or the bio-mineralization process \[[@B20-marinedrugs-17-00146],[@B21-marinedrugs-17-00146],[@B22-marinedrugs-17-00146],[@B23-marinedrugs-17-00146],[@B24-marinedrugs-17-00146]\]. Up to the present time, seven polyphyletic classes of CAs have been described and indicated with the Greek letters α, β, γ, δ, ζ, η and θ \[[@B19-marinedrugs-17-00146],[@B25-marinedrugs-17-00146],[@B26-marinedrugs-17-00146],[@B27-marinedrugs-17-00146]\]. Moreover, members of each class possess multiple transcript variants and protein isoforms, which are characterized by different biochemical properties and have specific tissue/organ and sub-cellular localizations \[[@B4-marinedrugs-17-00146],[@B5-marinedrugs-17-00146],[@B17-marinedrugs-17-00146],[@B28-marinedrugs-17-00146],[@B29-marinedrugs-17-00146],[@B30-marinedrugs-17-00146],[@B31-marinedrugs-17-00146]\]. For examples, CAs present in animals belong to α-class \[[@B32-marinedrugs-17-00146],[@B33-marinedrugs-17-00146]\], plants and algae have α-, β-, γ-, δ- and θ-classes; fungi encode for α- and β-CAs; protozoa for α-, β- and/or η-CAs; bacteria for α-, β- and γ-CA classes \[[@B30-marinedrugs-17-00146],[@B31-marinedrugs-17-00146],[@B34-marinedrugs-17-00146],[@B35-marinedrugs-17-00146],[@B36-marinedrugs-17-00146],[@B37-marinedrugs-17-00146],[@B38-marinedrugs-17-00146]\]. Intriguing, in the oyster *Pinctada fucata* a matrix protein, called nacrein, has been identified. It participates in the formation of the nacreous layer and is characterized by a CA domain present at the N-terminus part of the polypeptide sequence \[[@B39-marinedrugs-17-00146]\]. In mammals, 16 α-CA isoforms have been identified: Eight of them are cytosolic, five are membrane-bound, two are mitochondrial, and only one is secreted, the last three being devoid of catalytic activity and referred to as CA Related Proteins (CARPs) \[[@B16-marinedrugs-17-00146],[@B18-marinedrugs-17-00146],[@B27-marinedrugs-17-00146]\].

In corals, most of the available results on CAs were obtained by measuring the CA activity in crude tissue extracts using non-specific CA inhibitors or antibodies raised against human isoforms \[[@B6-marinedrugs-17-00146],[@B7-marinedrugs-17-00146],[@B14-marinedrugs-17-00146],[@B40-marinedrugs-17-00146],[@B41-marinedrugs-17-00146]\]. Recently, the development of molecular biology tools allowed the isolation and full characterization of several CA isoforms in different coral species, such as *Lobactis scutaria* \[[@B42-marinedrugs-17-00146]\], *Stylophora pistillata* \[[@B2-marinedrugs-17-00146],[@B8-marinedrugs-17-00146]\], and *Acropora millepora* \[[@B43-marinedrugs-17-00146]\]. In particular, our groups analyzing the molecular data in the branching coral *Stylophora pistillata* identified 16 α-CA isoforms in the transcriptome and genome of this scleractinian coral \[[@B2-marinedrugs-17-00146],[@B3-marinedrugs-17-00146],[@B8-marinedrugs-17-00146],[@B44-marinedrugs-17-00146],[@B45-marinedrugs-17-00146],[@B46-marinedrugs-17-00146],[@B47-marinedrugs-17-00146],[@B48-marinedrugs-17-00146]\]. Among them, two α-CAs were isolated (STPCA and STPCA-2, here, indicated as SpiCA1 and SpiCA2, respectively) and have been localized in the coral-calcifying cells, within the epithelium facing the skeleton \[[@B2-marinedrugs-17-00146],[@B8-marinedrugs-17-00146]\]. It has been proposed that SpiCA1 catalyzes the inter-conversion between the different inorganic forms of dissolved inorganic carbon at the site of calcification, whereas SpiCA2 is an intracellular enzyme, which is found as an organic matrix protein incorporated in the skeleton \[[@B49-marinedrugs-17-00146],[@B50-marinedrugs-17-00146]\]. Recently, a novel α-CA, named SpiCA3, which is cytoplasmic and ubiquitously expressed in all the coral cell layers, has been characterized \[[@B20-marinedrugs-17-00146]\]. This isoform showed a catalytic activity 1.14-times higher than human CA II and is one of the most effective CO~2~ catalysts among all CAs known to date with a k*~cat~* of 1.6 × 10^6^ s^−1^ and a k*~cat~*/K~M~ of 1.5 × 10^8^ M^−1^ s^−1^ \[[@B20-marinedrugs-17-00146]\]. Intriguingly, the three coral CAs (SpiCA1, SpiCA2, and SpiCA3) differ significantly in their catalytic activity and susceptibility to inhibition with anions \[[@B20-marinedrugs-17-00146]\]. Here, the sulfonamide inhibition profile of the SpiCA3 has been investigated for the first time. Sulfonamides and their bio-isosteres represent the most important class of CA inhibitors (CAIs). Furthermore, the SpiCA3 inhibition profile was compared with those obtained for SpiCA1 and SpiCA2 previously studied by our groups \[[@B45-marinedrugs-17-00146]\].

2. Results and Discussion {#sec2-marinedrugs-17-00146}
=========================

2.1. Recombinant Enzymes {#sec2dot1-marinedrugs-17-00146}
------------------------

The recombinant SpiCA1, SpiCA2, and SpiCA3 were obtained, as described earlier \[[@B2-marinedrugs-17-00146],[@B20-marinedrugs-17-00146],[@B44-marinedrugs-17-00146],[@B51-marinedrugs-17-00146],[@B52-marinedrugs-17-00146]\]. [Figure 1](#marinedrugs-17-00146-f001){ref-type="fig"} shows a multi-alignment of the three α-CA isoforms encoded by the genome *S. pistillata* and investigated up until now. It is readily apparent that the three coral isoforms show the main features of a typical mammalian α-CAs. They possess the conserved: (i) Three His ligands, which coordinate the Zn(II) ion crucial for catalysis, (His94, His96, and His119, hCA I numbering system); (ii) the two gate-keeping residues (Glu106 and Thr199), which are implicated in the substrate orientation and the binding of the inhibitors; and (iii) the proton shuttle residue (His64), which is involved in the transfer of the proton (H^+^) from the water coordinated to the Zn(II) ion to the environment, influencing and making very fast the rate of the catalytic reaction. Furthermore, SpiCA3, diversely from the other two coral isoforms, is a cytoplasmic protein. SpiCA1 and SpiCA2 are, in fact, secreted proteins characterized by the presence of a signal peptide at the N-terminal of their amino acid sequences (see [Figure 1](#marinedrugs-17-00146-f001){ref-type="fig"}). Interesting, the insertions and deletions of a relatively extended number of amino acid residues along the polypeptide chain, which affect the three coral isoforms ([Figure 1](#marinedrugs-17-00146-f001){ref-type="fig"}), may influence the kinetic and inhibition behavior of the coral enzymes, probably because of significant alterations of their three-dimensional structure. For example, SpiCA3 showed a k*~cat~* = 10^6^ s^−1^, which is one order of magnitude higher than the k*~cat~* (10^5^ s^−1^) of the other two isoforms.

2.2. Sulfonamide Used as CAIs {#sec2dot2-marinedrugs-17-00146}
-----------------------------

As described in the literature, it has been demonstrated that the sulfonamide CA inhibitors (CAIs), such as acetazolamide or ethoxzolamide, drastically decrease the coral calcification rates, with inhibition of up to 73% \[[@B50-marinedrugs-17-00146]\]. These data suggest that the coral CAs are finely tuned in providing carbonate and H^+^ ions for the control of the calcification process and pH homeostasis, respectively \[[@B6-marinedrugs-17-00146],[@B14-marinedrugs-17-00146],[@B53-marinedrugs-17-00146],[@B54-marinedrugs-17-00146]\]. Unfortunately, very few studies are available on the inhibition of the CAs encoded by coral genomes. The CAIs can be clustered into several different groups considering their binding mode to the enzyme active site \[[@B29-marinedrugs-17-00146],[@B55-marinedrugs-17-00146]\]: (1) The metal ion binders (anion, sulfonamides and their bioisosteres, dithiocarbamates, xanthates, etc.); (2) compounds which anchor to the zinc-coordinated water molecule/hydroxide ion (phenols, polyamines, thioxocoumarins, sulfocumarins); (3) compounds occluding the active site entrance, such as coumarins and their isosteres; (4) compounds binding out of the active site, such as an aromatic carboxylic acid derivative; and (5) inhibitors with an unknown binding mechanism, such as secondary/tertiary sulfonamides, protein tyrosine kinase inhibitors, and fullerenes, for which the X-ray crystallographic structure is unavailable \[[@B29-marinedrugs-17-00146]\]. The most investigated CAIs are the anions and the sulfonamides \[[@B19-marinedrugs-17-00146],[@B29-marinedrugs-17-00146],[@B56-marinedrugs-17-00146],[@B57-marinedrugs-17-00146]\]. A library of 40 compounds, 39 primary sulfonamides, and one sulfamate, were used as CAIs ([Figure 2](#marinedrugs-17-00146-f002){ref-type="fig"}). Derivatives **1--24** and **AAZ-HCT** are either simple aromatic/heterocyclic sulfonamides widely used as building blocks for obtaining new families of such pharmacological agents, or they are clinically used agents, among which acetazolamide (**AAZ**), methazolamide (**MZA**), ethoxzolamide (**EZA**), and dichlorophenamide (**DCP**) are the classical, systemically acting antiglaucoma CAIs. Dorzolamide (**DZA**) and brinzolamide (**BRZ**) are topically acting antiglaucoma agents; benzolamide (**BZA**) is an orphan drug belonging to this class of pharmacological agents.

Moreover, the zonisamide (**ZNS**), sulthiame (**SLT**), and the sulfamic acid ester topiramate (**TPM**) are widely used antiepileptic drugs. Sulpiride (**SLP**) and indisulam (**IND**) were also shown by our group to belong to this class of pharmacological agents, together with the COX2 selective inhibitors celecoxib (**CLX**) and valdecoxib (**VLX**). Saccharin (**SAC**) and the diuretic hydrochlorothiazide (**HCT**) are also known to act as CAIs. As shown in [Figure 3](#marinedrugs-17-00146-f003){ref-type="fig"}, sulfonamides, such as the clinically used derivatives acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, and brinzolamide, bind in a tetrahedral geometry to the Zn(II) ion in the deprotonated state, with the nitrogen atom of the sulfonamide moiety coordinated to Zn(II) and an extended network of hydrogen bonds, involving amino acid residues of the enzyme, also participating in the anchoring of the inhibitor molecule to the metal ion \[[@B19-marinedrugs-17-00146],[@B29-marinedrugs-17-00146],[@B55-marinedrugs-17-00146],[@B58-marinedrugs-17-00146]\]. The aromatic/heterocyclic part of the inhibitor interacts with the hydrophilic and hydrophobic residues of the catalytic cavity ([Figure 3](#marinedrugs-17-00146-f003){ref-type="fig"}) \[[@B19-marinedrugs-17-00146],[@B29-marinedrugs-17-00146],[@B56-marinedrugs-17-00146],[@B57-marinedrugs-17-00146]\].

2.3. CA Inhibition Data and Comparative Analysis {#sec2dot3-marinedrugs-17-00146}
------------------------------------------------

[Table 1](#marinedrugs-17-00146-t001){ref-type="table"} shows inhibition data of sulfonamides (and one sulfamate, TPM) against the human α-CAs (isoforms hCA I and hCA II) and the recombinant coral α-CA isoforms (SpiCA1, SpiCA2, and SpiCA3). Recently, our groups reported data for hCAI, hCAII, SpiCA1, and SpiCA2 earlier \[[@B8-marinedrugs-17-00146],[@B45-marinedrugs-17-00146]\]. The following should be noted regarding the inhibition of the three coral enzymes with the compounds investigated in this study:

*(i) High potency inhibitors*

Most of the tested sulfonamides were effective inhibitors of the coral isoform SpiCA1 with a K~i~ in the range of 16--92 nM. This is the case of the compounds **5**, **7**, **8**, **14**, **18**, **19**, **20**, **AAZ**, **MZA**, **EZA**, **DZA**, **BRZ**, **BZA**, **TMP**, **VLX**, **CLX**, **SLT**, and **SAC**. Intriguingly, the majority of these compounds were moderate inhibitors of SpiCA2 and SpiCA3 showing a K~I~ \> 100 nM. The SpiCA2 inhibition profile showed only one compound (**AAZ**) with a K~I~ \< 100 nM; while SpiCA3 was well inhibited by compounds **17**, **19**, **20**, **21**, **23**, **24**, and **IND**.

*(ii) Medium potency inhibitors*

A large number of simple aromatic sulfonamides, such as derivatives **2--20**, and the pharmacological sulfonamides **AAZ**, **MZA**, **EZA**, **DZA**, **BRZ**, **BZA**, **ZNS**, **TMP**, **SLP**, **IND**, **CLX**, **SLT**, and **SAC** showed moderate SpiCA2 inhibitory properties with a K~I~ in the range 105--868 nM. Intriguing, the sulfonamide inhibition profile of SpiCA2 was characterized mainly by moderate inhibitors ([Table 1](#marinedrugs-17-00146-t001){ref-type="table"}). The compounds, which resulted in effective and moderate inhibitors of SpiCA1 or moderate inhibitors of SpiCA2, such as **2**, **5**, **6**, **7**, **8**, **TMP**, **ZNS**, **SLP**, **CLX**, and **SAC** resulted in the worst inhibitors for the coral isoform SpiCA3. The majority of these derivatives are benzenesulfonamides with one or two simple substituents in ortho, para, or the 3,4-positions of the aromatic ring with respect to the sulfamoyl zinc-binding moiety.

*(iii) Ineffective inhibitors*

A large number of sulfonamides, such as derivatives **1**, **2**, **5**, **6**, **7**, **8**, **10**, **TPM**, **ZNS**, **SLP**, **VLX**, **CLX**, and **SAC** were weak inhibitors of SpiCA3 showing a K~i~ \> 1000 nM. Interesting, the coral isoform SpiCA2 showed only one ineffective derivative (**VLX**), while the SpiCA1 was the isoform better inhibited by all the compounds used in the present study.

*(iv) Human isoforms versus coral enzymes*

The comparison of the inhibition profile of the human isoforms with those of the coral enzymes showed that SpiCA1 resulted very similar to the isoform hCAII. Furthermore, the isoform hCAI was not inhibited by most of the derivatives indicated with the numbers **1**, **2,** and those of the range **4--17** (K~I~ \> 1000 nM). Moreover, the clinically used agents, among which DZA, BRZ, and CLX didn't affect the hCAI activity, while they were high potency inhibitors for hCAII and SpiCA1 and low potency inhibitors for SpCA2 and SpiCA3.

3. Material and Methods {#sec3-marinedrugs-17-00146}
=======================

3.1. Isoform Expression and Purification {#sec3dot1-marinedrugs-17-00146}
----------------------------------------

The recombinant SpiCA1, SpiCA2, and SpiCA3 were obtained, as described earlier \[[@B2-marinedrugs-17-00146],[@B20-marinedrugs-17-00146],[@B44-marinedrugs-17-00146],[@B51-marinedrugs-17-00146],[@B52-marinedrugs-17-00146]\]. Briefly, the BL21 DE3 competent cells (Agilent) were transformed with the recombinant vectors containing one of the three coral isoforms, grown at 37 °C and induced with 0.1 mM IPTG. After 30 min, ZnSO~4~ (0.5 mM) was added to the culture medium and cells were grown for an additional four h. Then, cells were harvested and re-suspended in the following buffer: 50 mM Tris/HCl, pH 8.0, 0.5 mM PMSF, and 1 mM benzamidine. Subsequently, bacterial cells containing the overexpressed CAs were disrupted by sonication at 4 °C and centrifugated at 12,000× *g* for 45 min. The resultant supernatant was loaded onto a His-select HF Nickel affinity column (GE Healthcare, dimension: 1.0 × 10.0 cm), equilibrated with 0.02 M phosphate buffer (pH 8.0) containing 0.01 M imidazole and 0.5 M KCl at a flow rate of 1.0 mL/min. The recombinant proteins were eluted from the column using 0.3 M imidazole, and then, dialyzed against 50 mM Tris/HCl, pH 8.3.

3.2. Amino Acid Sequence Analysis {#sec3dot2-marinedrugs-17-00146}
---------------------------------

Multi-alignment of amino acid sequences was performed using the program MUSCLE (MUltiple Sequence Comparison by Log-Expectation, EMBL-EBI in Hinxton, Cambridge (UK) Version 3.8), a new computer program for creating multiple alignments of protein sequence \[[@B59-marinedrugs-17-00146]\].

3.3. Enzyme Inhibition Profile {#sec3dot3-marinedrugs-17-00146}
------------------------------

An Applied Photophysics stopped-flow instrument (Leatherhead, Surrey (UK)) has been used for assaying the CA catalyzed CO~2~ hydration activity \[[@B60-marinedrugs-17-00146]\]. Phenol red (at a concentration of 0.2 mM) has been used as an indicator, working at the absorbance maximum of 557 nm, with 20 mM TRIS (pH 8.3) as buffer, and 20 mM NaClO~4~ (for maintaining constant the ionic strength), following the initial rates of the CA-catalyzed CO~2~ hydration reaction for a period of 10--100 s. The CO~2~ concentrations ranged from 1.7 to 17 mM for the determination of the kinetic parameters (by Lineweaver-Burk plots) and inhibition constants. For each inhibitor, at least six traces of the initial 5%--10% of the reaction have been used for determining the initial velocity. The un-catalyzed rates were determined in the same manner and subtracted from the total observed rates. Stock solutions of inhibitor (10--100 mM) were prepared in distilled-deionized water, and dilutions up to 0.01 mM were done after that with the assay buffer. Inhibitor and enzyme solutions were preincubated together for 15 min at room temperature before assay, to allow for the formation of the E-I complex or the eventual active site-mediated hydrolysis of the inhibitor. The inhibition constants were obtained by non-linear least-squares methods using PRISM 3 and the Cheng-Prusoff equation, as reported earlier \[[@B61-marinedrugs-17-00146],[@B62-marinedrugs-17-00146],[@B63-marinedrugs-17-00146]\], and represent the mean from at least three different determinations. All CA isoforms were recombinant ones obtained in-house. All salts/small molecules were of the highest purity available, from Sigma-Aldrich (Milan, Italy).

4. Conclusions {#sec4-marinedrugs-17-00146}
==============

In general, CAs are metalloenzymes integrated with a structural-functional complex of sequential enzymes \[[@B64-marinedrugs-17-00146],[@B65-marinedrugs-17-00146],[@B66-marinedrugs-17-00146]\] interconnected by metabolites produced from one catalyst and passed into the active site of another enzyme \[[@B64-marinedrugs-17-00146],[@B65-marinedrugs-17-00146]\]. For example, CA isoforms interact with bicarbonate transporters increasing the local bicarbonate concentration, and thus, accelerating the transmembrane bicarbonate movement, and modulating the pH at both sides of the plasma membranes \[[@B64-marinedrugs-17-00146],[@B66-marinedrugs-17-00146]\]. All these metabolic processes influence the coral physiology. Therefore, the study of the coral CA inhibition profiles may provide new insights to design experiments aimed at a better understanding of the molecular mechanisms involved in coral biomineralization and symbiosis. Furthermore, from the [Table 1](#marinedrugs-17-00146-t001){ref-type="table"}, it is readily apparent that the sulfonamide inhibition profile of the coral isoforms is substantially different from those of the cytosolic human isoforms, proving that it might be possible to design selective inhibitors using the scaffold of leads detected here for producing antiinfectives agents towards the pathogenic CAs \[[@B67-marinedrugs-17-00146]\]. The study of the inhibition profiles of new CAs, such as the coral ones, will give new advances in the synthesis of novel CAIs or in the modification/optimization of the existing inhibitors for making them more selective towards the pathogenic CAs.
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![This Multiple amino acid sequence alignment of the α-CAs encoded by the genome of *S. pistillata* (SpiCA1, SpiCA2, and SpiCA3). The main features of α-CA are indicated with different colors: zinc ligands are in blue; the "gate-keeper" residues are in orange; the histidine proton shuttle is in red; long stretches of 31 and 35 amino acid residues, in black bold. The insertion or deletion of amino acid residues are indicated with the grey transparent boxes, while the signal peptides typifying the SpiCA1 and SpiCA2 isoforms are included in the red transparent box. The symbol (\*) signifies identity at a position, while the symbols (:) and (.) designates conserved and semi-conserved substitutions, respectively. The SpiCA1 numbering system was used. The multiple sequence alignment was performed with the program Muscle Ver. 3.8. SpiCA1, *S. pistillata* isoform 1 (accession no. ACA53457.1); SpiCA2, *S. pistillata* isoform 2 (accession no. EU532164.1); and SpiCA3, *S. pistillata* isoform 3 (accession no. XP_022794253.1).](marinedrugs-17-00146-g001){#marinedrugs-17-00146-f001}

![38 sulfonamides and one sulfamate (Topiramate (TPM)) used for studying the inhibition profile of the three coral isoforms (SpiCA1, SpiCA2, and SpiCA3).](marinedrugs-17-00146-g002){#marinedrugs-17-00146-f002}

![Schematic representation of the metal binding mode of CAIs to human (h) CA isoform hCA II, such as sulfonamides and their bio-isosters.](marinedrugs-17-00146-g003){#marinedrugs-17-00146-f003}

marinedrugs-17-00146-t001_Table 1

###### 

Inhibition of human α-CAs (hCA I and hCA II) and the three recombinant enzyme from S. pistillata (SpiCA1, SpiCA2, and SpiCA3) with sulfonamides **1--24** and the clinically used drugs AAZ---HCT reported in [Figure 2](#marinedrugs-17-00146-f002){ref-type="fig"}.

  Inhibitor            K~I~ \* (nM)                
  ----------- -------- -------------- ----- ------ ----------
  **1**       28,000   300            \-    \-     5059
  **2**       25,000   240            364   300    4276
  **3**       79       8              \-    \-     667
  **4**       78,500   320            614   516    694
  **5**       25,000   170            83    508    7871
  **6**       21,000   160            94    577    7828
  **7**       8300     60             75    493    3318
  **8**       9800     110            88    551    1815
  **9**       6500     40             104   540    918
  **10**      7300     54             \-    \-     2532
  **11**      5800     63             367   481    856
  **12**      8400     75             295   840    430
  **13**      8600     60             105   361    275
  **14**      9300     19             92    357    578
  **15**      5500     80             \-    \-     487
  **16**      9500     94             \-    \-     199
  **17**      21,000   125            770   701    66
  **18**      164      46             30    661    241
  **19**      109      33             25    868    83
  **20**      6        2              28    333    74
  **21**      69       11             \-    \-     53
  **22**      164      46             \-    \-     568
  **23**      109      33             \-    \-     62
  **24**      95       30             \-    \-     46
  **AAZ**     250      12             16    74     737
  **MZA**     50       14             21    132    821
  **EZA**     25       8              39    105    56
  **DZA**     50,000   9              18    113    354
  **BRZ**     45,000   3              48    169    250
  **BZA**     15       9              20    214    394
  **TPM**     250      10             29    367    5828
  **ZNS**     56       35             259   645    5513
  **SLP**     1200     40             430   415    \>10,000
  **IND**     31       15             163   394    92
  **VLX**     54,000   43             29    5710   2918
  **CLX**     50,000   21             34    690    9102
  **SLT**     374      9              45    123    251
  **SAC**     18,540   5959           40    104    \>10,000
  **HCT**     328      290            \-    \-     243

\* Errors in the range of 5--10% of the reported data, from 3 different assays (data not shown) ^a^ Human recombinant isozymes and coral recombinant isoforms, stopped flow CO~2~ hydrase assay method, from References 12 and 45. - means not tested.
